Form 8-K - Current report:
SEC Accession No. 0001193125-24-140688
Filing Date
2024-05-16
Accepted
2024-05-16 17:01:16
Documents
13
Period of Report
2024-05-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d841479d8k.htm   iXBRL 8-K 25017
  Complete submission text file 0001193125-24-140688.txt   150948

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA alrn-20240515.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE alrn-20240515_lab.xml EX-101.LAB 18758
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alrn-20240515_pre.xml EX-101.PRE 11715
17 EXTRACTED XBRL INSTANCE DOCUMENT d841479d8k_htm.xml XML 3808
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Aileron Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 24956535
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)